Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

DOCS vs TEM: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DOCS Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

DOCS Overall Winner 6-Pillar Tally: DOCS 4 – 2 TEM Matrix Metrics: DOCS 7 – 3 TEM

As of Nov 17, 2026, Doximity, Inc. (DOCS) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DOCS carries a Unified Composite Score of 56.2/100 (HOLD) at $31.11 (20.2x Forward P/E, 27.1% operating margin), whereas TEM carries 43.5/100 (HOLD) at $63.43 (N/M Forward P/E, -18.5% operating margin).

  • Growth vs. Quality Trade-Off: DOCS earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. TEM 43.5/100 HOLD) and 0.69β · 43% Vol risk profile, whereas TEM leads top-line expansion (+23.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: DOCS trades in a Neutral technical trend (SURGE options phase, RSI 46.3); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DOCS vs TEM
DOCS NYSE Head-to-Head Winner
Doximity, Inc.
Services-Computer Programming Services
$31.11
-5.07% 1D
Market Cap $5.9B
TTM Revenue $662M
Forward P/E 20.2x
Beta / 30D Vol 0.69β · 43% Vol
Unified Composite Score
56.2 / 100 HOLD
Tech 40.0 Fund 51.0 Flow 58.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $33.13 · SMA50: $30.00
TEM NASDAQ
Tempus AI, Inc. Class A Common Stock
Services-Computer Programming, Data Processing, Etc.
$63.43
-2.05% 1D
Market Cap $13.1B
TTM Revenue $1.51B
Forward P/E N/M
Beta / 30D Vol 2.51β · 93% Vol
Unified Composite Score
43.5 / 100 HOLD
Tech 31.0 Fund 51.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 40
RSI-14: 40.3 · SMA20: $73.18 · SMA50: $72.83

6-Pillar Scorecard Institutional Category Breakdown (DOCS 4 – 2 TEM)

Columns: Metric · DOCS · TEM
1. Valuation Multiples DOCS
Forward P/E 20.2x N/M
Trailing P/E 46.3x N/M
PEG Ratio 0.59x N/M
EV / Revenue 8.7x 9.2x
2. Growth & Scale TEM
Revenue Growth (YoY) +3.6% +23.1%
Earnings Growth (YoY) -41.9% +0.0%
TTM Revenue (USD) $662M $1.51B
Market Cap $5.9B $13.1B
3. Profitability & Quality DOCS
Gross Margin 86.8% 64.5%
Operating Margin 27.1% -18.5%
Net Profit Margin 21.1% -12.5%
Return on Equity (ROE) 13.8% -37.5%
4. Balance Sheet & Cash Flow DOCS
Cash Generation (TTM) $297M -$151M
Cash Flow Margin 44.9% -10.0%
Net Cash / Leverage $209M Net Cash $841M Net Debt (2.86x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning DOCS
Options Structure Phase SURGE BREAKDOWN
Current IV / %ile 66.2% (52nd %ile) 99.3% (44th %ile)
Put/Call OI Skew 0.25x (Call-Skewed) 0.49x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat TEM
OpEx & R&D Intensity 59.7% of Rev ($395M) 83.0% of Rev ($1.25B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Ecosystem & Network-Effect Moat
Supply-Chain Role Health Information Services Operator Health Information Services Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DOCS (7) vs TEM (3)
Institutional Metric DOCS TEM Criterion Row Edge
Market Capitalization
Scale
$5.9B $13.1B Larger Scale TEM
Trailing P/E Ratio
Valuation
46.3x N/M Lower Multiple DOCS
Forward P/E Ratio
Valuation
20.2x N/M Lower Multiple DOCS
Revenue Growth (YoY)
Growth
+3.6% +23.1% Higher Growth TEM
Operating Margin (TTM)
Profitability
27.1% -18.5% Higher Margin DOCS
Net Profit Margin
Profitability
21.1% -12.5% Higher Margin DOCS
Return on Equity (ROE)
Capital Efficiency
13.8% -37.5% Higher ROE DOCS
52-Week Range Position
Momentum
40% ($17–$52) 47% ($41–$89) Stronger Trend TEM
Beta / 30D Volatility
Risk Regime
0.69β · 43% Vol 2.51β · 93% Vol Lower Realized Risk DOCS
Unified Institutional Score
Composite Signal
56.2 / 100 (HOLD) 43.5 / 100 (HOLD) Higher Composite DOCS
Trailing 12M Revenue (USD)
Operating Scale
$662M $1.51B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
86.8% 64.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.59x PEG · 8.7x EV/Rev N/M PEG · 9.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$297M ($209M Net Cash) -$151M ($841M Net Debt (2.86x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon DOCS +0.33 pp
DOCS: -1.08% · TEM: -1.41%
3M Horizon DOCS +17.26 pp
DOCS: +20.82% · TEM: +3.56%
6M Horizon DOCS +22.22 pp
DOCS: +61.53% · TEM: +39.31%
1Y Horizon TEM +29.93 pp
DOCS: -37.3% · TEM: -7.37%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DOCS Revenue TEM Revenue DOCS Op. Margin TEM Op. Margin Margin Leader
FY2020 $120M N/A 19.0% N/A DOCS
FY2021 $210M N/A 25.8% N/A DOCS
FY2022 $340M $320M 33.0% -82.8% DOCS
FY2023 $420M $530M 29.9% -36.9% DOCS
FY2024 $480M $690M 34.5% -99.7% DOCS
FY2025 $570M $1.27B 39.9% -19.9% DOCS
FY2026 $640M N/A 33.3% N/A DOCS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DOCS SURGE
14d in phase · OBV NEUTRAL
Current IV 66.2%
IV Percentile 52nd %ile
Put/Call OI Skew 0.25x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DOCS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
TEM BREAKDOWN
36d in phase · OBV DISTRIBUTION
Current IV 99.3%
IV Percentile 44th %ile
Put/Call OI Skew 0.49x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact TEM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $32.77 · IV 42.9%

DOCS vs. TEM: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of DOCS ($3,277) vs. TEM ($6,476) against risk-defined 5-day vertical and put-wall option structures.

DOCS Spot $32.77 · IV 42.9%
DOCS Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $32.5 / $35 Bull Call Spread

Buy 1x $32.5C · Sell 1x $35C · 32d

Net Entry $90 Debit
T+5d @ +5% Move +$41 (+46%)
Max Risk / Buffer $90 Capped
5d Edge & Liquidity 0.9x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $30 / $27.5 Bull Put Spread

Sell 2x $30P · Buy 2x $27.5P · 32d

Net Entry $58 Credit
Max Credit / Yield +$58 (+13.1% RoM)
Max Risk / Buffer -9.3% Cushion ($442 Mgn)
5d Edge & Liquidity 79% PoP · Liq B
Simulate 5-Day Payoff →
TEM Spot $64.76 · IV 84.1%
TEM Options Simulator →
5-DAY BULLISH SWING Liq A

Dec 18 $65 / $75 Bull Call Spread

Buy 1x $65C · Sell 1x $75C · 32d

Net Entry $365 Debit
T+5d @ +5% Move +$69 (+19%)
Max Risk / Buffer $365 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $60 / $55 Bull Put Spread

Sell 1x $60P · Buy 1x $55P · 32d

Net Entry $160 Credit
Max Credit / Yield +$160 (+47.1% RoM)
Max Risk / Buffer -9.8% Cushion ($340 Mgn)
5d Edge & Liquidity 68% PoP · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DOCS Moat Profile Scale & Operating Efficiency Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $5.9B market capitalization and 27.1% operating margin.
OpEx & R&D Reinvestment 59.7% of Rev ($395M)
90D Engineering Disclosures 0 Published
TEM Moat Profile Ecosystem & Network-Effect Moat
Health Information Services Operator
Competes within the Health Information Services value chain with $13.1B market capitalization and -18.5% operating margin.
OpEx & R&D Reinvestment 83.0% of Rev ($1.25B)
90D Engineering Disclosures 0 Published · AI Drug Discovery

Investor FAQ DOCS vs TEM Key Questions & Quantitative Answers

As of Nov 17, 2026, Doximity, Inc. (DOCS) is the stronger overall head-to-head candidate over Tempus AI, Inc. (TEM) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). DOCS carries a Unified Composite Score of 56.2/100 (HOLD) at $31.11 (20.2x Forward P/E, 27.1% operating margin), whereas TEM carries 43.5/100 (HOLD) at $63.43 (N/M Forward P/E, -18.5% operating margin). Growth vs. Quality Trade-Off: DOCS earns the overall head-to-head edge with a stronger Unified Composite Score (56.2/100 HOLD vs. TEM 43.5/100 HOLD) and 0.69β · 43% Vol risk profile, whereas TEM leads top-line expansion (+23.1% YoY revenue growth, N/M PEG, and 2 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: DOCS trades in a Neutral technical trend (SURGE options phase, RSI 46.3); meanwhile TEM is in a Breakdown options structure phase (RSI 40.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TEM leads the Growth & Scale pillar: DOCS posts +3.6% YoY revenue growth and -41.9% YoY earnings growth on $662M TTM revenue (86.8% gross margin, 27.1% operating margin), compared with TEM at +23.1% YoY revenue growth and +0.0% YoY earnings growth on $1.51B TTM revenue (64.5% gross margin, -18.5% operating margin). Across the 7-period historical trajectory (FY2020 to FY2026), DOCS cumulative revenue shifted +433.3% while TEM shifted +296.9%. In operating R&D and SG&A reinvestment, DOCS deploys 59.7% of Rev ($395M) (0 90-day corporate R&D disclosures) versus 83.0% of Rev ($1.25B) (0 disclosures) for TEM.

DOCS screens cheaper on headline valuation multiples. DOCS trades at 20.2x Forward P/E, 46.3x Trailing P/E, 0.59x PEG, and 8.7x EV/Revenue (44.9% FCF margin), whereas TEM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 9.2x EV/Revenue (-10.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DOCS (13.8% ROE) versus TEM (-37.5% ROE) capital efficiency.

In options market volatility and institutional positioning, DOCS carries 66.2% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 0.25x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.69β · 43% Vol realized risk). By comparison, TEM carries 99.3% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.49x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.51β · 93% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.